DRDejan Radenkovic

Dejan Radenkovic

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Dejan Radenkovic has a total of 126 co-authors. Here are the top co-authors by number of shared publications:

  • Adnan Alsourani

    General Surgery Department Hospital General Universitario Gregorio Marañón Madrid Spain

    1 shared publication
  • Alain Sauvanet

    Department of HPB Surgery, AP‐HP, Hôpital Beaujon University of Paris Clichy France

    1 shared publication
  • Alberto Balduzzi

    Unit of Pancreatic Surgery University of Verona Hospital Trust Verona Italy

    1 shared publication
  • Aleksandar Karamarkovic

    Zvezdara University Clinical Center, “Nikola Spasić” Surgical Clinic, Faculty of Medicine, University of Belgrade, Dimitrija Tucovica 161, 11000 Belgrade, Serbia

    1 shared publication
  • Alice Cattelani

    Unit of Pancreatic Surgery University of Verona Hospital Trust Verona Italy

    1 shared publication
  • Alice Clarkson

    Pancreatic Cancer UK London UK

    1 shared publication

Latest Publications

  • Open Access

    The European Multidisciplinary Evidence‐Based Guideline on Pancreatic Cancer: Methodological Protocol

    by Laura C. Leeuwenburgh, Magdalena Holze, Dena Akhoundzadeh, Adnan Alsourani, Ricardo Alvarez Jimenez, Paul C. M. Andel, Charlotte Baggerman van Houweninge, Alberto Balduzzi, Caro L. Bruna, Fabio Casciani, et al.

    Background: Pancreatic cancer remains one of the most lethal cancers despite extensive efforts and research conducted over the past decades. To effectuate groundbreaking improvements in pancreatic cancer treatment, interdisciplinary and international collaboration is essential. Evidence‐based guidelines, including state‐of‐the‐art evidence and expert opinion, are crucial to guide medical specialists, researchers, and patients, especially on issues where consensus is still lacking. This article describes the methodological protocol for the development of the European Multidisciplinary Evidence‐Based Guideline on Pancreatic Cancer. The guideline aims to identify current knowledge gaps on pancreatic cancer management, develop questions based on these knowledge gaps, and answer these questions with evidence‐based recommendations supplemented, when evidence is lacking, with expert advice for treatment and future research. Methods: This guideline development protocol is developed according to the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) methodology. The process is structured into six stages: First, 13 theme‐based multidisciplinary working groups are established, comprising representatives from 30 European medical and patient societies. Second, these working groups identify the most relevant current knowledge gaps on pancreatic cancer within their theme and formulate key questions. Third, the available evidence to answer these key questions is obtained through systematic reviews and the certainty of evidence is assessed using the GRADE approach. Fourth, recommendations are developed based on the available evidence. Fifth, all participants reach consensus on the recommendations through a modified Delphi process. Sixth, the recommendations are discussed during an open conference, including an external validation committee. Discussion: This methodological protocol of the European Multidisciplinary Evidence‐Based Guideline on Pancreatic Cancer is designed to identify key knowledge gaps across 13 themes and formulate evidence‐based recommendations. This guideline initiative unites 30 European medical and patient societies for pancreatic cancer.

  • Open Access

    A Review of Introductal Papillary Mucinous Neoplasia Classification, Surgical Indications, and Outcomes

    by V. Dordevic, M. Markovic, M. Protić, Đ. Knežević, D. Basarić, S. Antovic, N. Grubor, D. Radenković

    Intraductal papillary mucinous neoplasms (IPMNs) are pancreatic cystic lesions with malignant potential. This review outlines current guidelines, surgical indications, outcomes, and surveillance strategies. It also highlights recent advances in minimally invasive surgery and emerging biomarkers aimed at improving risk stratification and reducing unnecessary resections.

  • Open Access

    Spontaneous rupture of giant liver hemangioma: Case report

    by Krstina Doklestić, Branislav Stefanović, Aleksandar Karamarkovik, Vesna Bumbasirević, Branislava Stefanović, Pavle Gregorić, Dejan Radenković, Djordje Bajec

    Introduction. Hemangioma is the most frequent benign solid tumor of the liver. It is well known that a giant liver hemangioma carries the risk of spontaneous rupture, followed by hemoperitoneum and hemorrhagic shock with possible fatal outcome. Case Outline. This is a case report of the spontaneous rupture of a giant cavernous hemangioma of the liver in an 85-year old patient. The patient was presented with abdominal pain and hemorrhagic shock. Emergency ultrasonography and computed tomography of the abdomen showed a heterogeneous ruptured solid tumor of the right liver lobe, multiple cysts in the left lobe and massive hemoperitoneum. The patient was successfully managed by immediate exploratory laparotomy, surgical enucleation of the hemangioma under intermittent inflow vascular occlusion, temporary perihepatic packing and planned second look relaparotomy. Conclusion. Immediate surgical procedure is indicated mandatory in unstable patients with a ruptured giant hemangioma of the liver. Surgical enucleation under intermittent inflow vascular occlusion and temporary perihepatic packing could be a life-saving procedure in those patients.